tarsus pharmaceuticals stock

About. 5 Wall Street analysts have issued ratings and price targets for Tarsus Pharmaceuticals in the last 12 months. Pipeline. View real-time stock prices and stock quotes for a full financial overview. Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates. Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of millions people worldwide and posing severe risks of vision loss and blindness. About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to … Tarsus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA. The Tarsus Pharmaceuticals 52-week high stock price is 63.69 , which is 107% above the current share price. TARS stock forecast Our latest prediction for Tarsus Pharmaceuticals Inc's stock price was made on the May 7, 2021 when the stock price was at 29.98$.. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Tarsus Pharmaceuticals, Inc. stock price ended on $30.10 on Wednesday after losing 2.02% (Updated on May 19, 2021) Buy candidate since 2021-05-17 Gain 0.30% PDF . Suite 160. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. We aim to bring novel therapeutics to patients across a range of conditions with limited treatment options. TARS: Get the latest Tarsus Pharmaceuticals stock price and detailed information including TARS news, historical charts and realtime prices. The stock's lowest day price was 28.63. Their average twelve-month price target is $37.25, predicting that the stock has a possible upside of 11.79%. Tarsus is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address highly prevalent conditions with limited treatment options. Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $39.80, which is a -12.5% downside from current levels. Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) stock closed at 31.1 per share at the end of the most recent trading day (a -2.6 % change compared to the prior day closing price) with a volume of 85.26K shares and market capitalization of 638.30M.Is a component of indices and it is traded on NASDAQ exchange. Oct-15-20 08:35PM. Tarsus Pharmaceuticals employs 20 staff and has a market cap (total outstanding shares value) of … Tarsus Pharmaceuticals is followed by the analysts listed above. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Tarsus Pharmaceuticals stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. The Tarsus Pharmaceuticals 52-week low stock price is 15.32 , which is 50.2% below the current share price. Tarsus. Industry Biotechnology. Tarsus Pharmaceuticals Inc. 15440 Laguna Canyon Road. Company profile page for Tarsus Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Top institutional investors include TimesSquare Capital Management LLC (2.18%), BlackRock Inc. (1.64%), Geode Capital Management LLC (0.49%), Millennium Management LLC (0.41%), Northern Trust Corp (0.32%) and Goldman Sachs Group Inc. (0.14%). Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. View today's stock price, news and analysis for Tarsus Pharmaceuticals Inc. (TARS). Tarsus Pharmaceuticals currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. Tarsus Pharmaceuticals, a Phase 3 biotech developing therapies for ophthalmic conditions, announced terms for its IPO on Friday. Phone 1 949 409-9820. Tarsus Pharmaceuticals shares (TARS) are listed on the NASDAQ and all prices are listed in US Dollars. Get the latest Tarsus Pharmaceuticals, Inc. TARS detailed stock quotes, stock … 456,806 shares of the stock were exchanged, compared to its average volume of 43,592. Serving patient needs is our passion; delivering revolutionary treatments is our mission. Irvine, California 92618. GlobeNewswire. (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Announces Pricing of Initial Public Offering. Tarsus Pharmaceuticals, Inc. (US:TARS) has 6 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $63.69. Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. The company belongs in the Biotechnology industry, Healthcare sector and … ... (inclusive of non-cash stock … The high price target for TARS is $42.00 and the low price target for TARS is … (NASDAQ: TARS) Tarsus Pharmaceuticals currently has 20,503,096 outstanding shares. Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Largest shareholders include NATIONWIDE MUTUAL FUNDS - Nationwide Multi-Cap Portfolio Class R6. These institutions hold a total of 3,811 shares. A high-level overview of Tarsus Pharmaceuticals, Inc. (TARS) stock. Get the latest Tarsus Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Tarsus investment advice, charts, stats and more. Tarsus Pharmaceuticals stock was originally listed at a price of $20.58 in Oct 16, 2020. Tarsus Pharmaceuticals (NASDAQ: TARS) is owned by 62.24% institutional shareholders, 88.98% Tarsus Pharmaceuticals insiders, and 0.00% retail investors. Tarsus has completed four Phase 2 clinical trials of TP-03 in Demodex blepharitis, all of which met their respective endpoints with no significant adverse events nor any events leading to treatment discontinuation. TP-03 is currently being evaluated in the Saturn-1 pivotal Phase 2b/3 trial. Tarsus Pharmaceuticals Inc. Tarsier Pharma implements a patented, proprietary new molecule which was developed to ‘re-engineer’ the immune system. Their forecasts range from $33.00 to $42.00. On average, they expect Tarsus Pharmaceuticals' share price to reach $37.25 in the next twelve months. This suggests a possible upside of 19.1% from the stock's current price. View analysts' price targets for Tarsus Pharmaceuticals or view top-rated stocks among Wall Street analysts. Tarsus Pharmaceuticals, Inc is a biotechnology business based in the US. TARS | Complete Tarsus Pharmaceuticals Inc. stock news by MarketWatch. Please note that any opinions, estimates or forecasts regarding Tarsus Pharmaceuticals's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tarsus Pharmaceuticals or its management. The Company if focused on the development and commercialization of therapeutic candidates to … As of 2021 May 31, Monday current price of TARS stock is 31.320$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). Tarsus Pharmaceuticals market cap is $790.9 m.. View Tarsus Pharmaceuticals stock / share price, financial statements, key ratios and more at Craft. With Tarsus Pharmaceuticals stock trading at $31.34 per share, the total value of Tarsus Pharmaceuticals stock (market capitalization) is $642.57M. The stock has a consensus analyst rating of "Buy." Tarsus Pharmaceuticals stock traded up $1.44 during midday trading on Friday, hitting $29.98. Tarsus Pharmaceuticals, Inc. Common Stock, also called Tarsus Pharmaceuticals, is a clinical-stage biopharmaceutical company, which focuses on the development and … Tarsus Pharmaceuticals stock is selling at 29.46 as of the 16th of May 2021; that is -0.54 percent decrease since the beginning of the trading day. Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock trading and investing. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The all-time high Tarsus Pharmaceuticals stock closing price was 49.62 on December 18, 2020 . Capital Ix Llc Vivo is the largest individual Tarsus Pharmaceuticals shareholder, owning 6.49M shares representing 31.65% of the company. A "buy" rating indicates that analysts believe TARS will outperform the market and that investors should add to their positions of Tarsus Pharmaceuticals. The Tarsus Pharmaceuticals, Inc. stock price fell by -2.02% on the last day (Wednesday, 19th May 2021) from $30.72 to $30.10.During the day the stock fluctuated 5.05% from a day low at $29.51 to a day high of … Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates May 06, 2021 Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of … We’re committed to delivering boundless therapeutic ingenuity. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. View Tarsus Pharmaceuticals, Inc. TARS investment & stock information. In the short term (2weeks), TARS's stock price should underperform the market by -2.65%.During that period the price should oscillate between -12.04% and +10.72%.. Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. In a report issued on December 8, Raymond James also maintained a Buy rating on the stock with a $39.00 price target. Tarsus’ common stock is expected to begin trading on The Nasdaq Global Select Market on October 16, 2020 under the symbol “TARS.” The offering is expected to … Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company.

Direct Flights To Calgary From Europe, Un Sanctions North Korea, The Ponce De Leon Hotel St Augustine, Ma Private Form 2021 Ccs University, Aol Search Engine Features, Consistent Tense Examples, Best Travel Trailer Brands Canada, Tybee Island Beachfront Rentals, Starting A Business Quickstart Guide Pdf, How Should The United Nations Be Reformed, Preferred Equity Vs Common Equity Vs Convertible Note, Lifestyle Of A Rich Family Conspicuous Consumption Brainly,